(Press-News.org) Results of a clinical trial seem to show the first effective treatment for the negative symptoms - withdrawal, lack of emotion, and apathy - associated with schizophrenia. This work is presented at the European College of Neuropsychopharmacology conference in Amsterdam.
Schizophrenia is one of the most common serious mental health conditions, with around 1 in 100 people experiencing schizophrenia in their lifetime*. The main symptoms fall into 3 categories: positive symptoms, such as delusions and hallucinations; negative symptoms, such as lack of drive and social withdrawal; and cognitive symptoms, such as problems with attention and memory. The negative symptoms tend to persist, and don't respond well to current treatment. Effective medicines (antipsychotics) exist for positive symptoms, but negative symptoms and cognitive impairment do not respond well to the available treatments.
Now the results of a new Phase III clinical trial indicate that the negative symptoms may be treatable with a new investigational drug, cariprazine, which binds to the D2 and D3 dopamine receptor with D3 preference. The researchers, all from the Gedeon Richter pharmaceutical company which developed the drug, enrolled 461 men and women in a randomised, double-blind clinical trial, to compare cariprazine against risperidone (which is commonly used to treat schizophrenia). Patients were treated for 26 weeks, with 77.4% of enrolled patients completing the trial. Full details of the trial are given in the abstract.
The outcomes were measured using a special subscale** of the PANSS scale (Positive and Negative Syndrome Scale) which is a standard method used for measuring symptom severity of patients with schizophrenia. After 26 weeks of treatment, it was found that cariprazine treatment group showed a statistically significant improvement in the PANSS-NFS scale relative to risperidone (-1.47; p=0.002). In addition to the effect on predominant negative symptoms of schizophrenia, patients who took cariprazine also performed significantly better on personal and social functioning than those who took risperidone. Full details of the trial are given in the abstract.
According to lead researcher Dr György Németh (Chief Medical Officer, Gedeon Richter):
"The positive symptoms of schizophrenia can be controlled by drugs, but this is the first study ever to show a significant effect of a compound on negative symptom compared to another antipsychotic. It seems that with cariprazine, we may be able to treat both the positive and negative symptoms with a single medication."
Commenting, ECNP Executive Committee Member Professor Andreas Meyer-Lindenberg said:
"Treatments for the negative symptoms of schizophrenia are still urgently needed as these are critical predictors for patient's recovery and reintegration. The current results suggest that D3-dopaminergic mechanisms may play a role in both causing and treating emotional flatness, which deserve further confirmation".
The trial was organised and supported by the Gedeon Richter pharmaceutical company, which developed cariprazine. The researchers report that the most frequent adverse events (incidence ?5%) across both treatments groups were insomnia, headache, akathisia, worsening of schizophrenia symptoms, anxiety and somnolence. As this drug has not yet completed the approval process, no indication of the costs of the treatment is available.
INFORMATION:
The ECNP receives no sponsorship from Gedeon Richter Plc we are reporting this as work presented at the ECNP annual conference.
Please note that the headline of this article has been shortened to comply with Eurekalert parameters.
An international group of researchers have found that food craving activates different brain networks between obese and normal weight patients. This indicates that the tendency to want food may be 'hard-wired' into the brain of overweight patients, becoming a functional brain biomarker.
Obesity is one of the most difficult problems facing modern society. Treating obesity is a health priority, but most efforts (aside from bariatric surgery) have met with little success. In part, this is because the mechanisms associated with the desire to eat are poorly understood. Recently, ...
Brain imaging shows that testosterone therapy given as part of sex reassignment changes the brain structures and the pathway associated with speech and verbal fluency. This result supports research that women in general may deal with speech and interaction differently than men.
The sex hormone testosterone exerts a substantial influence on human behaviour and cognition. Previous studies have shown that testosterone has a particular influence on verbal fluency. But these investigations (which due to ethical reasons are mostly observational studies or one-off hormone administrations) ...
According to the United States Centers for Disease Control and Prevention, over 800,000 Americans die each year from heart disease and stroke. Acute coronary syndrome, which includes heart attack and unstable angina, a condition that can lead to a heart attack, are among the leading causes of death and disability worldwide. In addition to lifestyle changes, medications that lower blood cholesterol are helpful in preventing future cardiac and vascular events, including heart attack and stroke.
New data from a clinical trial led by cardiologists at Brigham and Women's ...
London, UK - 30 Aug 2015: Efforts to improve automated external defibrillator (AED) usage increase bystander defibrillation in public places but not at home, reveals a study of more than 25 000 cardiac arrest patients presented at ESC Congress today by Dr Steen Hansen, a PhD student in the Department of Health, Science and Technology at Aalborg University in Denmark.1 Efforts included increased numbers of AEDs, cardiopulmonary resuscitation (CPR) education and a nationwide AED registry.
"An AED promptly used by a person present at the cardiac arrest site before the emergency ...
London, UK - 30 Aug 2015: Bystander cardiopulmonary resuscitation (CPR) has been linked to a 30% lower risk of nursing home admission and brain damage in survivors of cardiac arrest outside hospital in research presented at ESC Congress today by Dr Kristian Kragholm, a PhD student in the Department of Anesthesiology, Cardiovascular Research Centre, Aalborg University Hospital, Denmark.1
"We know that survival after out-of-hospital cardiac arrest has improved in recent years but until now the degree of disability in survivors was unknown," said Dr Kraghom. "Our study examined ...
London, UK - 30 Aug 2015: Ezetimibe reduces cardiovascular events in patients with diabetes and a recent acute coronary syndrome, according to a subgroup analysis of the IMPROVE-IT trial presented at ESC Congress today by co-principal investigator Dr Robert Giugliano, physician in cardiovascular medicine at Brigham and Women's Hospital in Boston, US.1 Ezetimibe achieved greater reductions in LDL cholesterol than statins alone, resulting in lower risks of cardiovascular events in patients with diabetes. The benefits observed in diabetics were greater than in those without ...
London, UK - 30 Aug 2015: Particulate matter and NO2 air pollution are associated with increased risk of severe heart attacks despite being within European recommended levels, according to research presented at ESC Congress today by Dr Jean-Francois Argacha, a cardiologist at University Hospital Brussels (UZ Brussel-Vrije Universiteit Brussel), in Belgium.1
"Dramatic health consequences of air pollution were first described in Belgium in 1930 after the Meuse Valley fog," said Dr Argacha. "Nowadays, the World Health Organization (WHO) considers air pollution as one of ...
London, UK - 30 Aug 2015: Young adults living in a polluted city show early signs of cardiovascular risk, according to research presented at ESC Congress today by Dr Krzysztof Bryniarski from Jagiellonian University, Collegium Medicum in Krakow, Poland.1 Residing in a polluted city was associated with higher levels of inflammatory markers in otherwise healthy adolescents and young adults, which indicate a greater risk of having a heart attack in future.
Dr Bryniarski said: "This study was conducted by a group of medical students from Jagiellonian University in Krakow, ...
London, UK - 30 Aug 2015: Cold weather is associated with a higher risk of severe heart attack, according to research presented at ESC Congress today by Dr Shuangbo Liu, adult cardiology resident at the University of Manitoba in Winnipeg, Canada.1 The six year study found that each 10°C drop in temperature was associated with a 7% increased risk of ST-elevation myocardial infarction (STEMI), the most severe form of heart attack.
"We studied the effects of temperature on the risk of heart attacks in Winnipeg, Canada, one of the coldest large cities in the world," said ...
London, UK - 30 Aug 2015: Cardiopulmonary resuscitation (CPR) for out-of-hospital cardiac arrest should be conducted for at least 35 minutes, according to research presented at ESC Congress today by Dr Yoshikazu Goto, associate professor and director of the Department of Emergency and Critical Care Medicine at Kanazawa University Hospital in Kanazawa, Japan.1 The study in more than 17 000 patients found that nearly all survivals were achieved within 35 minutes and longer CPR achieved little benefit.
Dr Goto said: "The decision regarding when to stop resuscitation efforts ...
